According to a new study, funded in part by The ALS Association, published today in the Journal of Clinical Investigation, scientists have identified a biomarker in the blood that signals the earliest stages of the disease.
While further studies to validate this finding will be important, this exciting discovery suggests that the immune system plays an important role early in the disease process of ALS and may provide doctors with a means of monitoring the progression of the disease through a simple blood test.
This research was conducted by researchers at Harvard Medical School, Tufts Medical School, Brigham and Women’s Hospital and Massachusetts General Hospital.
Significance of this study:
“This new biomarker provides us with a tool to better understand the beginning stages of ALS and may allow us to track the disease with a simple blood test,” said Lucie Bruijn, Ph.D. Chief Scientist for The ALS Association, “That is critical for developing new treatments. Furthermore, the immune system changes identified in this study may themselves offer new targets for treating ALS.”
Currently, the only way to track the progression of ALS is through clinical measurements, such as the ALS Functional Rating Scale (ALS-FRS), and measures of muscle strength that fluctuate over the short term, leading to the need for long-term clinical trials with large numbers of patients.
Behind the science:
In this study, which was led by Howard Weiner, M.D., of Harvard Medical School and Brigham and Women’s Hospital, researchers used the standard laboratory model of ALS, a mouse containing the mutant gene for SOD1. SOD1 was the first gene discovered to cause familial ALS, the inherited form of the disease.
In the mouse model, researchers found that a type of white blood cell, called a monocyte, developed a specific chemical “signature” in the very earliest stages of the disease, before the mouse had developed symptoms. That signature triggered those cells to move to the spinal cord, where they increased inflammation, an important component of the ALS disease process. A similar signature was seen in monocytes of people with ALS. Scientists targeted the signature on monocytes in the mice using antibodies, which typically identify and neutralize foreign objects. This process slowed disease progression, suggesting that it may be a promising lead for developing therapies for people suffering from ALS.
For more information:
For questions about this and other research studies, please submit questions to email@example.com. If you are a member of the media, please submit inquiries to firstname.lastname@example.org.